Called $CRDO bullish on Sep 4, 2025: $CRDO rose 24% in 8 weeks.
View call →
Growth Stock Forum founder. Seeking Alpha author. Investor. Trader.
Cite asCryptoQuant has tracked the directional calls on ABBV by @ONeilTrader on X since Jun 2019: not yet scored on ABBV (as of Nov 11, 2026).
2 ABBV calls on record, a thin history.
Relative view by default: fewer than 30 ABBV calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @ONeilTrader to submit corrections.
Called $CRDO bullish on Sep 4, 2025: $CRDO rose 24% in 8 weeks.
View call →Hover the chart to read the thesis of that period · click a day to pin it
$ABBV lutikizumab topline results in hidradenitis suppurativa. Not very convincing, but AbbVie is planning combos with amylin analog and TL1A antibody. https://t.co/bCIEvZj5It https://t.co/ga1xIY6wbM
View original →Published an article on $GMAB @SeekingAlpha examining the phase 3 success of Epkinly in frontline DLBCL and last weekend's phase 2 results of Rina-S in PROC patients. Partner $ABBV also a beneficiary of Epkinly's success and $RHHBY to see more competition to Polivy (but also positive read-through to its T-cell engager Columvi). https://t.co/3O7XDo1nMq
View original →$GMAB and $ABBV that's a nice win for Epkinly. 51% risk reduction is better than I expected (wanted to see 40%+), and better when compared across trials to Polivy (27% risk reduction initially, declined to 23% later). https://t.co/rDkxPm8N6O
View original →Published an article @SeekingAlpha looking at the new $REGN and $SNY deal. It's almost like they combined forces to create their own Apogee, now part of $ABBV https://t.co/WOpWqSOT0B https://t.co/1r8jy9Obn6
View original →$PFE tilrekimig data presentation in atopic dermatitis. Could compete with Dupixent ($REGN/SNY), Ebglyss ($LLY), zumilokibart ($ABBV), and others https://t.co/HhueqLlNte
View original →
